Unit for Translational Research in Oncology

Research domain

The main goal of our research is to perform top-level ‘bench-to-bedside’ translational oncology research. Starting from a clinical need and patient samples, we create, using a strong expertise in generating genetic models, reliable in vitro (e.g. by mimicking genetic aberrations in established cell lines, generate patient-derived primary cultures and organoids) and in vivo models (transgenic mouse models, patient-derived xenografts). These models allow us to identify novel tumor suppressors and oncogenes, define their mode of action, identify up/downstream drugable nodes and potential prognostic biomarkers using state-of-the-art genomics and proteomics, validate them and eventually screen for compounds that can perturb their oncogenic functions.


Research topic

  • Evaluating repurposing drugs for the treatment of metastatic breast cancer and colorectal cancer
  • Targeting transcription factor addiction in acute leukemia
  • Expanding the use of alternative less immunogenic and less toxic ASNase formulations for the treatment of solid cancers
  • Developing novel preclinical models for aggressive subtypes of leukemia/lymphoma